ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

11009	Companies
241218	Keywords
169768	Articles
129844	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 07/25/2025 at 08:00, 1 year 1 month ago

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax announces full exercise of underwriters’ option to purchase additional ADSs, bringing gross proceeds of offering to $747.5M (€637.5M). Company to apply net proceeds to identified use of funds

Abivax Underwriters ADSs Offering Proceeds
BRIEF

published on 07/24/2025 at 14:45, 1 year 1 month ago

Abivax's $650M Public Offering of ADS

Biotechnology Abivax Capital Increase Public Offering Ads
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year 1 month ago

Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax announces the trading resumption of its ordinary shares on Euronext Paris after a temporary halt for a public offering confirmation and pricing announcement

Euronext Paris Abivax Public Offering Clinical-stage Biotechnology Trading Resumption
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year 1 month ago

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
Abivax announces pricing of $650M (€554M) public offering of American Depositary Shares to fund clinical development and working capital, with expected closing on July 28, 2025

Abivax Clinical Development Public Offering Pricing Closing
BRIEF

published on 07/24/2025 at 07:35, 1 year 1 month ago

Abivax Temporarily Halts Trading on Euronext Paris

Euronext Paris Biotechnology Abivax Trading Halt Public Offering
PRESS RELEASE

published on 07/24/2025 at 07:30, 1 year 1 month ago

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris due to public offering preparations

Euronext Paris Abivax Trading Halt Public Offering Clinical-stage Biotechnology
BRIEF

published on 07/23/2025 at 22:20, 1 year 1 month ago

Abivax Launches $400 Million Public Offering

Ulcerative Colitis Clinical Development Capital Market Abivax Public Offering Biotechnology Financing
PRESS RELEASE

published on 07/23/2025 at 22:15, 1 year 1 month ago

Abivax Announces Launch of Public Offering
Abivax announces launch of $400 million public offering to fund therapeutics for chronic inflammatory diseases. Underwritten by Leerink Partners, Piper Sandler, Guggenheim Securities, with LifeSci Capital, BTIG, Van Lanschot Kempen as managers

Biotechnology Financing Abivax Underwriters Public Offering
BRIEF

published on 07/22/2025 at 22:10, 1 year 1 month ago

Abivax Announces Positive Phase 3 Results for Obefazimod in Ulcerative Colitis

Abivax Obefazimod Ulcerative Colitis Phase 3 Trials MiR-124 Enhancer
PRESS RELEASE

published on 07/22/2025 at 22:05, 1 year 1 month ago

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
Abivax announces positive Phase 3 results for obefazimod in ulcerative colitis trials, meeting key endpoints and demonstrating favorable tolerability. Conference call scheduled for more insights

Abivax Obefazimod Ulcerative Colitis Clinical Trials Phase 3 Results

Accesswire

Published on 09/17/2026 at 10:00, 1 hour 4 minutes ago

Eagle Plains Reports Additional Results from Drilling at the Don Lake Uranium Project, Saskatchewan
Published on 09/16/2026 at 23:45, 11 hours 19 minutes ago

Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 13 hours 34 minutes ago

Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 18 hours 9 minutes ago

CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 20 hours 4 minutes ago

2026 Canada's Top 40 Under 40(R) Honourees Announced

View all ACCESSWIRE

EQS Group

Published on 09/17/2026 at 10:41, 23 minutes ago

elumeo SE successfully completes a cash capital increase
Published on 09/17/2026 at 10:40, 24 minutes ago

Making the Most of Every Ray, Powering the Unpowered: 2026 Global Low-Carbon Industry Forum Explores Pathways to Bridge the Electricity Gap
Published on 09/17/2026 at 10:05, 58 minutes ago

Geely Farizon Debuts Full-Spectrum Electric Commercial Vehicle Lineup at IAA Transportation 2026
Published on 09/17/2026 at 10:05, 59 minutes ago

Avalara Appoints Claire Goad as General Manager of E-Invoicing and Live Reporting
Published on 09/17/2026 at 09:49, 1 hour 15 minutes ago

Kirchhoff analysis: Most AGM speeches in the SDAX are overly complex and lack accessibility

Les Echos

Published on 09/16/2026 at 20:46, 14 hours 18 minutes ago

LNA SANTE : 2026 First Half Results
Published on 09/16/2026 at 17:45, 17 hours 19 minutes ago

5th edition of “On the way up” show
Published on 09/16/2026 at 17:45, 17 hours 19 minutes ago

Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 4 hours ago

bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 17 hours ago

Report on the Combined General Meeting of the 10th of September 2026

View all LES ECHOS COMFI WIRE